FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055962337> ?p ?o ?g. }

• W2055962337 endingPage "641" @default.
• W2055962337 startingPage "631" @default.
• W2055962337 abstract "ObjectiveChemoresistance remains a major clinical obstacle to curative chemotherapy of acute myeloid leukemia (AML), but the molecular mechanisms underlying resistance to chemotherapeutic agents used in AML are largely unknown. We have attempted to investigate genetic mechanisms causing resistance to Ara-C [1-β-D-arabinofuranosyl-cytosine (cytarabine)], one mainstay in AML chemotherapy for decades.Material and MethodsHighly Ara-C-resistant murine BXH-2 strain AML cell lines were generated, and their molecular changes were compared to their sensitive parental lines. The causative changes were confirmed using a genetic approach.ResultsWe derived nine highly Ara-C-resistant murine BXH-2 strain AML sublines via in vitro selection. p21Cip1 was dramatically downregulated and p53 protein accumulation induced by Ara-C treatment was impaired in one resistant line. In this line, repeated Ara-C exposure had selected for cells that harbor a genomic deletion affecting the splicing of Trp53 mRNA. This deletion produces an aberrant Trp53 mRNA, in which exon 4 is skipped, producing a protein lacking parts of both the transactivation and DNA-binding domains. Retroviral transduction of the sensitive parental cells with a dominant-negative Trp53 cDNA caused changes in the protein levels of p21Cip1, BAX, and cleaved caspase-3, but not bcl-XL, and rendered the cells more resistant to Ara-C. Unexpectedly, we found that pifithrin-α (PFTα), a compound that has been proposed to regulate p53 protein activity, induced apoptosis in both Ara-C-sensitive and -resistant lines, and decreased Ara-C resistance in cells with either normal or mutant Trp53 genes.ConclusionsThese data indicate that Trp53 loss-of-function could partly explain the acquisition of AML chemoresistance, and suggest that PFTα could be useful in treatment of relapsed AML. Chemoresistance remains a major clinical obstacle to curative chemotherapy of acute myeloid leukemia (AML), but the molecular mechanisms underlying resistance to chemotherapeutic agents used in AML are largely unknown. We have attempted to investigate genetic mechanisms causing resistance to Ara-C [1-β-D-arabinofuranosyl-cytosine (cytarabine)], one mainstay in AML chemotherapy for decades. Highly Ara-C-resistant murine BXH-2 strain AML cell lines were generated, and their molecular changes were compared to their sensitive parental lines. The causative changes were confirmed using a genetic approach. We derived nine highly Ara-C-resistant murine BXH-2 strain AML sublines via in vitro selection. p21Cip1 was dramatically downregulated and p53 protein accumulation induced by Ara-C treatment was impaired in one resistant line. In this line, repeated Ara-C exposure had selected for cells that harbor a genomic deletion affecting the splicing of Trp53 mRNA. This deletion produces an aberrant Trp53 mRNA, in which exon 4 is skipped, producing a protein lacking parts of both the transactivation and DNA-binding domains. Retroviral transduction of the sensitive parental cells with a dominant-negative Trp53 cDNA caused changes in the protein levels of p21Cip1, BAX, and cleaved caspase-3, but not bcl-XL, and rendered the cells more resistant to Ara-C. Unexpectedly, we found that pifithrin-α (PFTα), a compound that has been proposed to regulate p53 protein activity, induced apoptosis in both Ara-C-sensitive and -resistant lines, and decreased Ara-C resistance in cells with either normal or mutant Trp53 genes. These data indicate that Trp53 loss-of-function could partly explain the acquisition of AML chemoresistance, and suggest that PFTα could be useful in treatment of relapsed AML." @default.
• W2055962337 created "2016-06-24" @default.
• W2055962337 creator A5005626540 @default.
• W2055962337 creator A5025451142 @default.
• W2055962337 creator A5027828146 @default.
• W2055962337 creator A5035774267 @default.
• W2055962337 creator A5050213589 @default.
• W2055962337 date "2006-05-01" @default.
• W2055962337 modified "2023-09-27" @default.
• W2055962337 title "Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia" @default.
• W2055962337 cites W140845169 @default.
• W2055962337 cites W1480734369 @default.
• W2055962337 cites W1489284756 @default.
• W2055962337 cites W1496387664 @default.
• W2055962337 cites W1547619885 @default.
• W2055962337 cites W1598625800 @default.
• W2055962337 cites W1672289351 @default.
• W2055962337 cites W180295822 @default.
• W2055962337 cites W1843554028 @default.
• W2055962337 cites W1851609974 @default.
• W2055962337 cites W1916039573 @default.
• W2055962337 cites W1923175699 @default.
• W2055962337 cites W1935990934 @default.
• W2055962337 cites W1979319210 @default.
• W2055962337 cites W1981570437 @default.
• W2055962337 cites W1982420043 @default.
• W2055962337 cites W1985986955 @default.
• W2055962337 cites W1991364405 @default.
• W2055962337 cites W1992556088 @default.
• W2055962337 cites W2007315663 @default.
• W2055962337 cites W2013136213 @default.
• W2055962337 cites W2021300545 @default.
• W2055962337 cites W2026389791 @default.
• W2055962337 cites W2030873172 @default.
• W2055962337 cites W2054507539 @default.
• W2055962337 cites W2057607894 @default.
• W2055962337 cites W2060618478 @default.
• W2055962337 cites W2068140004 @default.
• W2055962337 cites W2070476377 @default.
• W2055962337 cites W2073820895 @default.
• W2055962337 cites W2082770850 @default.
• W2055962337 cites W2083087888 @default.
• W2055962337 cites W2083089310 @default.
• W2055962337 cites W2089405975 @default.
• W2055962337 cites W2101091611 @default.
• W2055962337 cites W2103109018 @default.
• W2055962337 cites W2124106713 @default.
• W2055962337 cites W2128060680 @default.
• W2055962337 cites W2137013563 @default.
• W2055962337 cites W2139211474 @default.
• W2055962337 cites W2140716778 @default.
• W2055962337 cites W2153172903 @default.
• W2055962337 cites W2320078260 @default.
• W2055962337 cites W2619218625 @default.
• W2055962337 doi "https://doi.org/10.1016/j.exphem.2006.01.015" @default.
• W2055962337 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16647569" @default.
• W2055962337 hasPublicationYear "2006" @default.
• W2055962337 type Work @default.
• W2055962337 sameAs 2055962337 @default.
• W2055962337 citedByCount "39" @default.
• W2055962337 countsByYear W20559623372012 @default.
• W2055962337 countsByYear W20559623372013 @default.
• W2055962337 countsByYear W20559623372014 @default.
• W2055962337 countsByYear W20559623372015 @default.
• W2055962337 countsByYear W20559623372016 @default.
• W2055962337 countsByYear W20559623372017 @default.
• W2055962337 countsByYear W20559623372019 @default.
• W2055962337 countsByYear W20559623372020 @default.
• W2055962337 countsByYear W20559623372021 @default.
• W2055962337 crossrefType "journal-article" @default.
• W2055962337 hasAuthorship W2055962337A5005626540 @default.
• W2055962337 hasAuthorship W2055962337A5025451142 @default.
• W2055962337 hasAuthorship W2055962337A5027828146 @default.
• W2055962337 hasAuthorship W2055962337A5035774267 @default.
• W2055962337 hasAuthorship W2055962337A5050213589 @default.
• W2055962337 hasBestOaLocation W20559623371 @default.
• W2055962337 hasConcept C104317684 @default.
• W2055962337 hasConcept C1292079 @default.
• W2055962337 hasConcept C143065580 @default.
• W2055962337 hasConcept C150194340 @default.
• W2055962337 hasConcept C153911025 @default.
• W2055962337 hasConcept C190283241 @default.
• W2055962337 hasConcept C202751555 @default.
• W2055962337 hasConcept C2778041864 @default.
• W2055962337 hasConcept C2778461978 @default.
• W2055962337 hasConcept C2778729363 @default.
• W2055962337 hasConcept C36823959 @default.
• W2055962337 hasConcept C501734568 @default.
• W2055962337 hasConcept C502942594 @default.
• W2055962337 hasConcept C54355233 @default.
• W2055962337 hasConcept C81885089 @default.
• W2055962337 hasConcept C86803240 @default.
• W2055962337 hasConceptScore W2055962337C104317684 @default.
• W2055962337 hasConceptScore W2055962337C1292079 @default.
• W2055962337 hasConceptScore W2055962337C143065580 @default.
• W2055962337 hasConceptScore W2055962337C150194340 @default.
• W2055962337 hasConceptScore W2055962337C153911025 @default.
• W2055962337 hasConceptScore W2055962337C190283241 @default.

• next